Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)

被引：6

作者：

Curigliano, G. ^{[1
]}

Dunton, K. ^{[2
]}

Rosenlund, M. ^{[3
]}

Janek, M. ^{[4
]}

Cathcart, J. ^{[5
]}

Liu, Y. ^{[6
]}

Fasching, P. A. ^{[7
,8
]}

Iwata, H. ^{[9
]}

机构：

[1] Univ Milan, Dept Oncol & Hematooncol, European Inst Oncol IRCCS, Milan, Italy

[2] Dauchi Sankyo Europe GmbH, Global Hlth Econ Outcomes Res & Real World Eviden, Munich, Germany

[3] Dauchi Sankyo Europe GmbH, Global Oncol HEOR & RWE, Munich, Germany

[4] Daiichi Sankyo, Global Med Affairs, Braine Lalleud, Belgium

[5] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA

[6] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA

[7] Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany

[8] Comprehens Canc Ctr, Erlangen, Germany

[9] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

来源：

关键词：

D O I：

10.1016/j.annonc.2022.03.182

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

163O

引用

页码：S196 / S197

页数：2